Cargando…

Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients

BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in different countries. Liver fibrosis is considered as the most appropriate predictor of NAFLD‐associated outcome. Microfibrillar‐associated protein 4 (MFAP4) is a glycoprotein located in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanaan, Reine, Yaghi, Cesar, Saade Riachy, Carole, Schlosser, Anders, Hamade, Aline, Holmskov, Uffe, Medlej‐Hashim, Myrna, Sørensen, Grith Lykke, Jounblat, Rania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037036/
https://www.ncbi.nlm.nih.gov/pubmed/36968563
http://dx.doi.org/10.1002/jgh3.12873
_version_ 1784911796257161216
author Kanaan, Reine
Yaghi, Cesar
Saade Riachy, Carole
Schlosser, Anders
Hamade, Aline
Holmskov, Uffe
Medlej‐Hashim, Myrna
Sørensen, Grith Lykke
Jounblat, Rania
author_facet Kanaan, Reine
Yaghi, Cesar
Saade Riachy, Carole
Schlosser, Anders
Hamade, Aline
Holmskov, Uffe
Medlej‐Hashim, Myrna
Sørensen, Grith Lykke
Jounblat, Rania
author_sort Kanaan, Reine
collection PubMed
description BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in different countries. Liver fibrosis is considered as the most appropriate predictor of NAFLD‐associated outcome. Microfibrillar‐associated protein 4 (MFAP4) is a glycoprotein located in the extracellular matrix. Circulatory MFAP4 has been suggested as a noninvasive biomarker for the assessment of hepatitis C virus and alcoholic liver disease associated liver fibrosis. In this study, we aimed to investigate the association between serum MFAP4 and liver fibrosis severity in NAFLD patients. METHODS: A case–control study was conducted in which NAFLD patients (n = 25) and healthy participants (n = 12) were recruited. Liver fibrosis/cirrhosis was assessed by transient elastography (TE) and biochemical parameters were collected. Serum MFAP4 was measured by sandwich ELISA based on two monoclonal anti‐MFAP4 antibodies and calibrated with a standard of recombinant MFAP4. RESULTS: Serum MFAP4 levels increased with fibrosis severity and were highly upregulated in patients with cirrhosis (F4 fibrosis stage). In addition, serum MFAP4 levels positively correlated with TE measurement and showed significant association with the severely advanced fibrotic stage in NAFLD patients, in multiple linear regression analysis following adjustment for age, gender, and body mass index. CONCLUSION: This study suggests the use of MFAP4 as a potential diagnostic noninvasive biomarker for cirrhosis screening in NAFLD patients.
format Online
Article
Text
id pubmed-10037036
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-100370362023-03-25 Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients Kanaan, Reine Yaghi, Cesar Saade Riachy, Carole Schlosser, Anders Hamade, Aline Holmskov, Uffe Medlej‐Hashim, Myrna Sørensen, Grith Lykke Jounblat, Rania JGH Open Original Articles BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in different countries. Liver fibrosis is considered as the most appropriate predictor of NAFLD‐associated outcome. Microfibrillar‐associated protein 4 (MFAP4) is a glycoprotein located in the extracellular matrix. Circulatory MFAP4 has been suggested as a noninvasive biomarker for the assessment of hepatitis C virus and alcoholic liver disease associated liver fibrosis. In this study, we aimed to investigate the association between serum MFAP4 and liver fibrosis severity in NAFLD patients. METHODS: A case–control study was conducted in which NAFLD patients (n = 25) and healthy participants (n = 12) were recruited. Liver fibrosis/cirrhosis was assessed by transient elastography (TE) and biochemical parameters were collected. Serum MFAP4 was measured by sandwich ELISA based on two monoclonal anti‐MFAP4 antibodies and calibrated with a standard of recombinant MFAP4. RESULTS: Serum MFAP4 levels increased with fibrosis severity and were highly upregulated in patients with cirrhosis (F4 fibrosis stage). In addition, serum MFAP4 levels positively correlated with TE measurement and showed significant association with the severely advanced fibrotic stage in NAFLD patients, in multiple linear regression analysis following adjustment for age, gender, and body mass index. CONCLUSION: This study suggests the use of MFAP4 as a potential diagnostic noninvasive biomarker for cirrhosis screening in NAFLD patients. Wiley Publishing Asia Pty Ltd 2023-02-23 /pmc/articles/PMC10037036/ /pubmed/36968563 http://dx.doi.org/10.1002/jgh3.12873 Text en © 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Kanaan, Reine
Yaghi, Cesar
Saade Riachy, Carole
Schlosser, Anders
Hamade, Aline
Holmskov, Uffe
Medlej‐Hashim, Myrna
Sørensen, Grith Lykke
Jounblat, Rania
Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients
title Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients
title_full Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients
title_fullStr Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients
title_full_unstemmed Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients
title_short Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients
title_sort serum mfap4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in nafld patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037036/
https://www.ncbi.nlm.nih.gov/pubmed/36968563
http://dx.doi.org/10.1002/jgh3.12873
work_keys_str_mv AT kanaanreine serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients
AT yaghicesar serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients
AT saaderiachycarole serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients
AT schlosseranders serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients
AT hamadealine serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients
AT holmskovuffe serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients
AT medlejhashimmyrna serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients
AT sørensengrithlykke serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients
AT jounblatrania serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients